Announcement on 3/29 that Olympus and Sony have again delayed the start of a joint venture to develop medical equipment because they have yet to gain approval from some regulators.
My guess is that this may hold up resolution of the Cytori/Olympus JV issue. Although Olympus holds approximately 7% of Cytori common shares and certainly would not want to diminish the Cytori SP in the event the JV is dissolved, it would seem that for all the years of effort and cash that Olympus invested that it would require some compensation for the dissolution. That compensation could be in the form of a cash/stock settlement or future royalties. Kaas, WST, JG, Hedgefund, Roth, etc., what are your thoughts in regard to the potential compensation.
No doubt the terms of any dissolution are spelled out in the contract, and since I don't know these details, it is very hard to speculate on the impact on CYTX. But I can comment on Japanese regulators. I think they may be slower and more vexing than our FDA!
Considering all the billions sqanderef by Olympus and all the other issues they are dealing with, I imagine the Cytori JV is a low priority for Olympus. Not a pressing matter for Cytori given the next generation unit to be developed under BARDA, hopefully